SHRP2 R02 Phase 1 — Geotechnical Solutions for Soil Improvement, Rapid Embankment Construction, and Stabilization of the Pavement Working Platform

Author(s):  
V. R. Schaefer ◽  
G. M. Filz ◽  
L. S. Vanzler
Keyword(s):  
Phase 1 ◽  
2020 ◽  
Vol 224 (3) ◽  
pp. 1811-1824
Author(s):  
Sina Saneiyan ◽  
Dimitrios Ntarlagiannis ◽  
Frederick Colwell

SUMMARY Soil stabilization processes aim at enhancing soil's engineering properties. Although the concept is straightforward, it involves physical and chemical changes to the subsurface that could result in local environmental changes. Compared to conventional soil stabilization methods (such as cement grouting), bio-mediated soil stabilization, such as microbial-induced calcite precipitation (MICP), offers the opportunity to minimize environmental impact, but the underlying processes need to be well understood for proper applications. Accurate characterization and long-term monitoring are paramount for the success of soil improvement, especially MICP treatments. Spectral induced polarization (SIP), an established geophysical method, has shown to be sensitive to MICP processes and products (e.g. calcite). In this work, we performed a two-phase study to explore SIP's suitability as a monitoring tool. Phase 1 involved a laboratory scale MICP study under controlled conditions and phase 2 a pilot field scale study. In the laboratory, MICP was induced through the introduction of ureolytic microorganisms, while in the field, indigenous soil microbes were stimulated to promote ureolysis. In both cases, traditional geochemical monitoring, along with spatiotemporally dense SIP monitoring, were performed. Over the course of the laboratory study, SIP successfully tracked the MICP progress as well as the calcite precipitation behaviour. Similarly, the SIP results of the field scale study showed to be sensitive to the subsurface changes in response to MICP. SIP offered spatiotemporally rich information on the MICP progress and process status. The similarity between observed signal trends in the laboratory and field in this study clearly proved that SIP signals from MICP in controlled laboratory environments can be successfully used to study field MICP applications despite scale and complexity differences.


2001 ◽  
Vol 60 (4) ◽  
pp. 215-230 ◽  
Author(s):  
Jean-Léon Beauvois

After having been told they were free to accept or refuse, pupils aged 6–7 and 10–11 (tested individually) were led to agree to taste a soup that looked disgusting (phase 1: initial counter-motivational obligation). Before tasting the soup, they had to state what they thought about it. A week later, they were asked whether they wanted to try out some new needles that had supposedly been invented to make vaccinations less painful. Agreement or refusal to try was noted, along with the size of the needle chosen in case of agreement (phase 2: act generalization). The main findings included (1) a strong dissonance reduction effect in phase 1, especially for the younger children (rationalization), (2) a generalization effect in phase 2 (foot-in-the-door effect), and (3) a facilitatory effect on generalization of internal causal explanations about the initial agreement. The results are discussed in relation to the distinction between rationalization and internalization.


2004 ◽  
Author(s):  
Carl L. Henderson
Keyword(s):  
Phase 1 ◽  

2012 ◽  
Vol 13 (05) ◽  
Author(s):  
A Schmitz ◽  
A Bareksei ◽  
B Paul ◽  
C Schulz
Keyword(s):  

2011 ◽  
Vol 08 (03) ◽  
pp. 150-156
Author(s):  
A. Szegedi

ZusammenfassungDie Medikamentenentwicklung in der Psychiatrie hat kürzlich eine Paradigmenkrise durchlaufen, deren Ursache an verschiedenen allgemeinen Entwicklungen und spezifischen Faktoren im psychiatrischen Fachgebiet liegt. Unter die allgemeinen Entwicklungen fallen deutlich gestiegene Kosten bei der Medikamentenentwicklung und die zunehmende Komplexität bei der Durchführung klinischer Studien, wohingegen sich die Produktivität der Medikamentenentwicklung insgesamt nicht erhöht hat. Die Anforderungen an neue Medikamente der Zulassungsbehörden wie auch der Kostenträger im Gesundheitswesen haben sich generell erhöht. Diese Faktoren zwingen die pharmazeutische Industrie, ihre Ressourcen auf die erfolgversprechendsten Gebiete zu fokussieren. Die spezifischen Probleme der Psychiatrie beinhalten fehlendes detailliertes Wissen zur Pathophysiologie vieler psychiatrischer Störungen, unzureichende prädiktive Tiermodelle, fehlende valide Biomarker, steigende Placeboresponse sowie die grundlegende Problematik der neurobiologisch heterogenen Diagnosen. Aus diesem Grund haben viele forschende Unternehmen bei der Entwicklung neuer Medikamente für die Psychiatrie ihre Prioritäten überdacht. Im Fokus des Artikels stehen Fragen zu Schwächen und potenziellen Risiken im Rahmen psychiatrischer Phase-1- und -2-Studien. Im Lichte dieser jüngsten Entwicklungen werden die spezifischen Probleme für Patienten und Therapeuten aus langfristiger Perspektive diskutiert.


Sign in / Sign up

Export Citation Format

Share Document